Do not use bisphosphonate therapy indefinitely for fracture prevention

Prescrire International

Volumn 17, Issue 97, 2008, Pages 214-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO;

BONE NECROSIS; CLINICAL TRIAL; DRUG EFFICACY; ESOPHAGUS DISEASE; EYE DISEASE; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; FRACTURES, SPONTANEOUS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 67649389578     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (2)

1. Prescrire Editorial Staff "Osteodensitometry in healthy postmenopausal women" Prescrire Int 2008; 17 (94): 68-72.
2. Black DM et al. "Effects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): a randomised trial" JAMA 2006; 296: 2927-2938.